Welcome to our dedicated page for First Tracks Biotherapeutics SEC filings (Ticker: TRAXV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on First Tracks Biotherapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into First Tracks Biotherapeutics's regulatory disclosures and financial reporting.
First Tracks Biotherapeutics Chief Financial Officer Ajim Tamboli received new equity awards as part of compensation. On May 12, 2026, he was granted options to purchase 13,600 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036.
The option vests 25% on May 12, 2027 and then in equal monthly installments over the following three years, contingent on continued service. He also received 5,000 restricted stock units, with 25% of the RSUs vesting annually starting on May 12, 2027, also subject to continued service.
In addition to this new grant of 13,600 options, he holds other options covering up to 123,700 shares of common stock that vest according to their existing terms. These awards are non-cash grants and do not represent open-market share purchases or sales.
First Tracks Biotherapeutics Chief Medical Officer Paul F. Lizzul received new equity awards. He was granted employee stock options for 72,300 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036. These options vest 25% on May 12, 2027, then 1/48 of the total shares monthly until fully vested, contingent on continued service.
He also received 26,700 restricted stock units, each representing a right to receive one share of common stock for no cash payment. The RSUs vest 25% annually starting on May 12, 2027, subject to ongoing service. There were no open-market purchases or sales reported. A footnote states he also holds separate options to purchase up to 507,310 shares of common stock that vest under their own terms.
First Tracks Biotherapeutics, Inc. is registering 10,497,054 shares of common stock for resale by existing stockholders under a Form S-1 registration statement. The company will not receive any proceeds from these resale transactions.
First Tracks was spun off from AnaptysBio, Inc. on April 20, 2026 and now trades on Nasdaq under the symbol TRAX, with a May 7, 2026 closing price of $17.82 per share. In a March 2026 private placement tied to the spin-off, First Tracks sold 5,791,479 primary shares and investors purchased 4,705,575 secondary shares at $13.81 per share, generating approximately $80 million in gross proceeds for the company.
First Tracks is a clinical-stage biotechnology company developing immunology therapeutics for autoimmune and inflammatory diseases, led by antibodies rosnilimab, ANB033 and ANB101. The business reported a 2025 net loss of $166.1 million and had $238.2 million in cash and cash equivalents as of December 31, 2025, and expects its existing cash, cash equivalents and investments to fund its current operating plan beyond the next 12 months. The company qualifies as an emerging growth company and a smaller reporting company, allowing reduced disclosure and compliance obligations.
First Tracks Biotherapeutics Chief Financial Officer Ajim Tamboli reported equity compensation awards in the form of stock options and restricted stock units. He received employee stock options to buy 41,234, 41,233 and 41,233 shares of common stock at exercise prices of $19.00, $18.87 and $17.00 per share, each expiring in 2036. He also received 45,700 restricted stock units, each representing the right to receive one share for no cash payment. The options vest 25% on April 20, 2027 and then monthly, while the RSUs vest 25% on the same date and then in equal annual installments, in each case contingent on continued service.
First Tracks Biotherapeutics, Inc. filed an initial Form 3 for Chief Financial Officer Ajim Tamboli. A Form 3 is used to disclose an insider’s starting ownership when they first become a reporting person. In this filing data, no transactions or specific share holdings are listed.
First Tracks Biotherapeutics ownership disclosure: EcoR1 Capital, LLC and affiliated reporting persons state beneficial ownership of Common Stock following a distribution received April 20, 2026. EcoR1 and Oleg Nodelman each report 3,174,519 shares (9.1% of the class); EcoR1 Capital Fund Qualified, L.P. reports 2,981,908 shares (8.5%). The reporting persons received 7,880,094 shares in the distribution and sold 4,705,575 shares in a private placement on the distribution date. Shares outstanding are listed as 34,892,381 as of April 20, 2026.
First Tracks Biotherapeutics, Inc. insider filing shows funds advised by EcoR1 Capital, LLC sold 4,705,575 shares of Common Stock at $13.8134 per share in a transaction coded as an open-market or private sale.
According to the disclosure, the shares are held directly by EcoR1-managed funds for the benefit of their investors, with EcoR1 and its control person Oleg Nodelman only indirectly deemed beneficial owners to the extent of their pecuniary interests. A footnote states the funds sold these shares in a private placement described in a separate Form 8-K.
The filing notes that EcoR1 Capital Fund Qualified L.P. sold 4,420,064 of the shares in this transaction and, after the sale, holds 2,981,908 First Tracks Biotherapeutics common shares. Overall indirect holdings reported for EcoR1 after the transaction total 3,174,519 shares, indicating the funds retain a sizable, but reduced, position.
EcoR1 Capital, LLC filed an initial Form 3 for First Tracks Biotherapeutics, Inc., reporting indirect beneficial ownership of 7,880,094 shares of Common Stock held by its investment funds. A key fund, EcoR1 Capital Fund Qualified L.P., beneficially owns 7,401,972 shares. These shares were received by the funds through a pro rata distribution of First Tracks Common Stock by AnaptysBio, Inc. on April 20, 2026, which the filing states qualified for the exemption provided by Rule 16a-9 under the Exchange Act.
First Tracks Biotherapeutics, Inc. Chief Business Officer Benjamin Stone has filed a Form 3 showing his equity holdings in the company. He directly holds 17,262 shares of common stock, including shares received in the spin-off of First Tracks from AnaptysBio.
Stone also holds performance stock units covering 50,000 underlying shares of common stock that vest based on performance metrics, with potential vesting dates in July 2025, July 2026 and July 2028. In addition, he has multiple tranches of restricted stock units, including awards tied to annual 25% vesting schedules beginning in January 2024, January 2025, January 2026 and January 2027.
The filing further lists several employee stock options with exercise prices ranging from $3.97 to $11.75 per share and expirations between 2032 and 2036, reflecting a mix of fully vested and time-vested option grants that align with his ongoing service to the company.
Lizzul Paul F. reported acquisition or exercise transactions in this Form 4 filing.
First Tracks Biotherapeutics, Inc. Chief Medical Officer Paul F. Lizzul reported equity awards and holdings tied to the spin-off from AnaptysBio, Inc. On the common stock line, he is shown holding 42,669 shares directly.
Footnotes explain that these shares, as well as stock options and restricted stock units, were received or adjusted in connection with a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks. Multiple RSU awards and stock options over First Tracks common stock were listed, with future vesting over several years, reflecting compensation and spin-off adjustments rather than open-market trading.